摘要
目的探讨LINC00858通过靶向miR-363-3p对肝癌HCCLM3细胞生物学行为的影响。方法选取2017年1月至2019年1月青海省第五人民医院收治的肝癌病人30例,获取其肝癌组织及其癌旁组织。设置si-NC组、si-LINC00858组、siLINC00858+anti-miR-NC组和si-LINC00858+anti-miR-363-3p组。实时荧光定量聚合酶链式反应(RT-qPCR)检测LINC00858和miR-363-3p表达水平;双荧光素酶报告实验验证LINC00858和miR-363-3p的靶向关系;CCK-8检测细胞增殖活性;Transwell检测细胞迁移和侵袭;蛋白质印迹法(Western blotting)法检测相关蛋白表达。结果肝癌组织中LINC00858高表达(2.85±0.27),miR-363-3p低表达(0.58±0.05)。LINC00858靶向调控miR-363-3p;抑制LINC00858能够上调p21表达,下调细胞周期蛋白D1(CyclinD1)、基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)表达,降低细胞活力、迁移数、侵袭数(P<0.05)。干扰miR-363-3p表达逆转了抑制LINC00858表达对肝癌HCCLM3细胞增殖、迁移和侵袭的影响。结论抑制LINC00858通过靶向上调miR-363-3p抑制肝癌细胞的增殖、迁移和侵袭。
Objective To investigate the effects of LINC00858 on the biological behaviour of liver cancer HCCLM3 cells by targeting miR-363-3p.Methods si-NC group,si-LINC00858 group,si-LINC00858+anti-miR-NC group and si-LINC00858+anti-miR-363-3p group were set.RT-qPCR to detect the expressions of LINC00858 and miR-363-3p;dual luciferase report assay verified the targeting relationship between LINC00858 and miR-363-3p;Cell proliferation activity was test using CCK-8 methods;cell migration and invasion was evaluated using Transwell;and related proteins expression was analyzed using Western blot.Results In liver cancer tissues,LINC00858(2.85±0.27)is highly expressed and miR-363-3p(0.58±0.05)is lowly expressed.LINC00858 targeted regulation of miR-363-3p;LINC00858 inhibition could up-regulate p21 expression,down-regulate cyclinDl,MMP-2 and MMP-9 expression,and reduce the cell viability,migration number and invasion number(P<0.05).Interfering with the expression of miR-363-3p reversed the inhibitory effect of LINC00858 inhibition on HCCLM3 cells proliferation,migration and invasion.Conclusion Inhibition of LINC00858 inhibits the proliferation,migration and invasion of liver cancer cells by targeting up-regulation of miR-363-3p.
作者
杨隆良
马瑜
郭虎林
YANG Longliang;MA Yu;GUO Hulin(Department of General Surgery,The Fifth People's Hospital of Qinghai,Xining,Qinghai 810000,China;Department of Oncology,The Fifth People's Hospital of Qinghai,Xining,Qinghai 810000,China;Department of Hepatobiliary Surgery,Qinghai University Affiliated Hospital,Xining,Qinghai 810001,China)
出处
《安徽医药》
CAS
2021年第8期1601-1604,共4页
Anhui Medical and Pharmaceutical Journal